INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that the French version of the 2010 Reference Document, including the Annual Financial Report

Transparency directive : regulatory news

03/05/2011 00:00

PRESS RELEASE

   INNATE PHARMA ANNOUNCES THE RELEASE OF ITS REFERENCE DOCUMENT (IN FRENCH)

Marseilles, France, May 3, 2011

Innate Pharma (Euronext Paris: FR0010331421 - IPH) announces that the French
version of the 2010 Reference Document, including the Annual Financial Report,
is available on its website (www.innate-pharma.com) as well as on the website of
the AMF, the French stock-market authorities (www.amf-france.org).

The English version of the 2010 Reference Document will be made available on
Innate Pharma's website at the end of May 2011.

Hard copies are available upon request to the investor relations department of
the Company.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its most advanced drug-candidate is IPH 2101, an anti-KIR monoclonal
antibody potentiating NK cells activation currently in Phase II clinical trials
in hematologic cancers. Two of its antibody programs in chronic inflammation are
out-licensed to Novo Nordisk A/S.

Innate Pharma's key expertise is in immunopharmacology and antibody technology.
The Company has implemented in-house a large panel of molecular and cellular
assays and in vivo models for assessing the pharmacodynamics and
pharmacotoxicology of drug candidates. In addition, Innate Pharma has access to
a very large set of unique research tools in cellular immunology through its
worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma
is based in Marseilles, France, and had 85 employees as at March 31, 2011.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:
ISIN code      FR0010331421
Ticker code    IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                Alize Public Relations
Laure-Hélène Mercier         Caroline Carmagnol
Director, Investor Relations Phone:  +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87  Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com  caroline@alizerp.com

IPH_Reference Document 2010

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that the French version of the 2010 Reference Document, including the Annual Financial Report

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories